AR003428A1 - Derivados de pirimidindiona o triazindiona como antagonista de los receptores adrenergenicos alfa1, procedimiento para su preparacion, composicion farmaceutica que los contiene y uso de dichos compuestos para la preparacion de medicamentos. - Google Patents
Derivados de pirimidindiona o triazindiona como antagonista de los receptores adrenergenicos alfa1, procedimiento para su preparacion, composicion farmaceutica que los contiene y uso de dichos compuestos para la preparacion de medicamentos.Info
- Publication number
- AR003428A1 AR003428A1 ARP960103000A AR10300096A AR003428A1 AR 003428 A1 AR003428 A1 AR 003428A1 AR P960103000 A ARP960103000 A AR P960103000A AR 10300096 A AR10300096 A AR 10300096A AR 003428 A1 AR003428 A1 AR 003428A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkyloxy
- aryl
- preparation
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Un compuesto caracterizado porque comprende la fórmula (I), en donde: R1 es acetilamino, amino, ciano, trifluoroacetilamino, halo, hidro, hidroxi, nitro,metilsulfonilamino, 2-propiniloxi, un grupo elegido entre (C1-6)alquilo, (C3-6)-cicloalqui l(C1-4)alquilo, (C1-6)alquiloxi, (C3-6)cicloalquiloxi, C(3-6)cicloalquil(C1-4)alquiloxi y (C1-4)alquiltio (cuyo grupo está opcionalmente sustituido adicionalmente por uno a tres átomos de halo) o un grupo elegidoentre arilo, aril(C1-4)alquilo, heteroarilo, heteroarilC(1-4)alquilo, ariloxi, aril(C1-4)-alquiloxi, heteroariloxi y heteroaril(C1-4)-alquiloxi(cuyo arilo yheteroarilo están opcionalmente sustituidos adicionalmente por uno a dos radicales elegidos independientemente ente halo yciano);R2 es ciano,halo,hidro,hidroxi o un grupo elegido entre (C1-6)alquilo y (C1-6)alquiloxi (cuyo grupo está opcionalmente sustituido adicionalmente por uno a tres átomos de halógeno);R3 y R4 son ambos hidro o metilo o juntos son etileno;y R5es un grupo elegido de las fórmulas (a), (b), (c) y (d);en donde: X es C(O), CH2 ó CH(OH); Y es CH2ó CH(OH); Z es N ó C(R9), en donde R9 es hidro, (C1-6)alquilo o hidroxi; R6 es hidro, un grupo elegido entre (C1-6)alquilo, (C3-6)- cicloalquilo, (C3- 6)cicloalquil(C1-4)alquilo (cuyo grupo está opcionalmente sustituido adicionalmente por uno a tres átomos de halo) o un grupo elegido entre arilo, heteroarilo,aril(C1-4)-alquilo y heteroaril(C1-4)alquilo (cuyo arilo y heteroarilo están opcionalmente sustituidos adicionalmente por uno a tres radicales elegidosentre halo, ciano, (C1-6)alquiloxi (C1-6)-alquilo y arilo); R7 es (C1-6) alcanoilo, carbamoilo, ciano, di(C1-6)alquilamino, halo, hidro, hidroxi, hidroxiiminometilo, (C1-6)alquil -sulfonilo, (C1-6)alquiltio, un grupo elegido entre (C1-6)alquilo, (C3-6)cicloalquilo, (C1-6)alquiloxi y (C1-6)alquiloxi(C1-4)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48918395A | 1995-06-09 | 1995-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR003428A1 true AR003428A1 (es) | 1998-08-05 |
Family
ID=23942748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960103000A AR003428A1 (es) | 1995-06-09 | 1996-06-06 | Derivados de pirimidindiona o triazindiona como antagonista de los receptores adrenergenicos alfa1, procedimiento para su preparacion, composicion farmaceutica que los contiene y uso de dichos compuestos para la preparacion de medicamentos. |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP0748800B1 (es) |
JP (1) | JP2721147B2 (es) |
KR (1) | KR100446877B1 (es) |
CN (1) | CN1118459C (es) |
AR (1) | AR003428A1 (es) |
AT (1) | ATE201016T1 (es) |
AU (1) | AU710754B2 (es) |
BR (1) | BR9602705A (es) |
CA (1) | CA2178548A1 (es) |
CO (1) | CO4700472A1 (es) |
CZ (1) | CZ290004B6 (es) |
DE (1) | DE69612698T2 (es) |
DK (1) | DK0748800T3 (es) |
ES (1) | ES2157366T3 (es) |
GR (1) | GR3036307T3 (es) |
HK (1) | HK1013065A1 (es) |
HU (1) | HU223594B1 (es) |
IL (1) | IL118519A (es) |
MA (1) | MA23899A1 (es) |
MY (1) | MY113499A (es) |
NO (1) | NO309424B1 (es) |
NZ (1) | NZ286720A (es) |
PE (1) | PE46497A1 (es) |
PL (1) | PL188061B1 (es) |
PT (1) | PT748800E (es) |
RU (1) | RU2175322C2 (es) |
SA (1) | SA96170263B1 (es) |
SG (1) | SG45486A1 (es) |
TR (1) | TR970073A2 (es) |
TW (1) | TW340846B (es) |
UY (1) | UY24257A1 (es) |
ZA (1) | ZA964561B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6271234B1 (en) | 1997-08-01 | 2001-08-07 | Recordati S.A., Chemical And Pharmaceutical Company | 1,4-disubstituted piperazines |
ATE294779T1 (de) | 1997-10-31 | 2005-05-15 | Daiichi Suntory Pharma Co Ltd | Arylpiperidinopropanol und arylpiperazinopropanol derivate und die selbe enthaltende pharmazeutika |
US6083950A (en) * | 1997-11-13 | 2000-07-04 | Ranbaxy Laboratories Limited | 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers |
DE69931100T2 (de) * | 1998-03-30 | 2007-04-19 | F. Hoffmann-La Roche Ag | Verfahren zu Fabrikation von Alpha 1l-Adrenorezeptor Antagonisten |
SK932001A3 (en) * | 1998-07-21 | 2001-08-06 | Ranbaxy Lab Ltd | ARYLPIPERAZINE DERIVATIVES USEFUL AS UROSELECTIVEì (54) ALPHA1-ADRENOCEPTOR BLOCKERS |
AU1979799A (en) * | 1998-07-21 | 2000-02-14 | Ranbaxy Laboratories Limited | Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers |
WO2000029386A1 (en) | 1998-11-12 | 2000-05-25 | Merck & Co., Inc. | Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists |
US6358959B1 (en) | 1999-01-26 | 2002-03-19 | Merck & Co., Inc. | Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists |
US6306861B1 (en) | 1999-07-30 | 2001-10-23 | Recordati S.A. Chemical And Pharmaceutical Company | Thienopyrancecarboxamide derivatives |
US6387909B1 (en) | 1999-07-30 | 2002-05-14 | Recordati S.A. Chemical And Pharmaceutical Company | Thienopyranecarboxamide derivatives |
GB2355264A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355263A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355456A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355457A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists |
US6403594B1 (en) | 1999-10-18 | 2002-06-11 | Recordati, S.A. Chemical And Pharmaceutical Company | Benzopyran derivatives |
US6365591B1 (en) | 1999-10-18 | 2002-04-02 | Recordati, S.A., Chemical And Pharmacueticals Company | Isoxazolecarboxamide derivatives |
MXPA02006848A (es) | 2000-01-25 | 2002-12-13 | Neurocrine Bioscience Inc | Antagonistas del receptor de la hormona liberadora de gonadotropina. |
CN1230423C (zh) * | 2000-11-30 | 2005-12-07 | 兰贝克赛实验室有限公司 | 可有效用作尿-选择性α1-肾上腺素能受体封阻剂的1,4-双取代的哌嗪衍生物 |
WO2003011841A1 (en) * | 2001-08-02 | 2003-02-13 | Neurocrine Biosciences, Inc. | 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists |
DE10311065A1 (de) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
CN1894234A (zh) | 2003-03-25 | 2007-01-10 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
US7723344B2 (en) | 2003-08-13 | 2010-05-25 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
MY140489A (en) * | 2003-12-26 | 2009-12-31 | Eisai R&D Man Co Ltd | 1,2-di (cyclic) substituted benzene compounds |
GB0400290D0 (en) | 2004-01-08 | 2004-02-11 | Medivir Ab | dUTPase inhibitors |
CN102134230B (zh) | 2004-03-15 | 2019-06-28 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
EP1655288A1 (en) * | 2004-11-05 | 2006-05-10 | Institut Pasteur | Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents |
CN101068798B (zh) | 2004-12-20 | 2010-05-12 | 卫材R&D管理有限公司 | 1-环丙基甲基-4-[2-(3,3,5,5-四甲基环己基)苯基]哌嗪的盐及结晶 |
EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2006126635A1 (ja) * | 2005-05-25 | 2006-11-30 | Eisai R & D Management Co., Ltd. | [2-(3,3,5,5-テトラメチルシクロヘキシル)フェニル]ピペラジン化合物の製造中間体 |
SI1942898T2 (sl) | 2005-09-14 | 2014-08-29 | Takeda Pharmaceutical Company Limited | Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa |
CN102675221A (zh) * | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
DE102008030091B4 (de) | 2008-06-25 | 2011-03-03 | Resprotect Gmbh | Uracilderivate und deren Verwendung |
US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
RU2449994C1 (ru) * | 2011-03-10 | 2012-05-10 | Светлана Алексеевна Мещерякова | 6-(4-бензилпиперазино)-1,3-диметилурацила дигидрохлорид, проявляющий биологическую активность |
WO2012129074A1 (en) * | 2011-03-18 | 2012-09-27 | Corcept Therapeutics, Inc. | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
GB201318886D0 (en) * | 2013-10-25 | 2013-12-11 | Givaudan Sa | Improvements i or relating to organic compounds |
ES2819830T3 (es) | 2016-03-17 | 2021-04-19 | Hoffmann La Roche | Derivado de 5-etiol-4-metil-pirazol-3-carboxamida que tiene actividad como agonista de TAAR |
JPWO2021085389A1 (es) * | 2019-10-28 | 2021-05-06 | ||
EP4344545A1 (en) * | 2021-04-28 | 2024-04-03 | Nippon Soda Co., Ltd. | Agricultural and horticultural fungicidal composition |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2727469A1 (de) * | 1977-06-18 | 1978-12-21 | Hoechst Ag | Neue hexahydropyrimidine, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
JPH02184667A (ja) * | 1989-01-11 | 1990-07-19 | Meiji Seika Kaisha Ltd | N,n’―ジ置換ピペラジル誘導体及びそれを有効成分とする排尿障害改善剤 |
JPH0344379A (ja) * | 1989-07-13 | 1991-02-26 | Yamasa Shoyu Co Ltd | N↑3―ピペラジノウラシル誘導体 |
JP2814600B2 (ja) * | 1989-08-31 | 1998-10-22 | 正幸 石川 | 排尿障害治療剤 |
HRP930210A2 (en) * | 1992-02-25 | 1995-06-30 | Recordati Chem Pharm | Heterobicyclic compounds and pharmaceutical preparations containing them |
FR2727682A1 (fr) * | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
-
1996
- 1996-05-28 AT AT96108493T patent/ATE201016T1/de not_active IP Right Cessation
- 1996-05-28 DE DE69612698T patent/DE69612698T2/de not_active Expired - Fee Related
- 1996-05-28 PT PT96108493T patent/PT748800E/pt unknown
- 1996-05-28 EP EP96108493A patent/EP0748800B1/en not_active Expired - Lifetime
- 1996-05-28 DK DK96108493T patent/DK0748800T3/da active
- 1996-05-28 ES ES96108493T patent/ES2157366T3/es not_active Expired - Lifetime
- 1996-05-31 IL IL11851996A patent/IL118519A/xx not_active IP Right Cessation
- 1996-06-03 AU AU54690/96A patent/AU710754B2/en not_active Ceased
- 1996-06-03 ZA ZA964561A patent/ZA964561B/xx unknown
- 1996-06-04 NZ NZ286720A patent/NZ286720A/en unknown
- 1996-06-05 PL PL96314635A patent/PL188061B1/pl not_active IP Right Cessation
- 1996-06-05 HU HU9601529A patent/HU223594B1/hu not_active IP Right Cessation
- 1996-06-06 AR ARP960103000A patent/AR003428A1/es active IP Right Grant
- 1996-06-06 PE PE1996000428A patent/PE46497A1/es not_active Application Discontinuation
- 1996-06-06 MA MA24270A patent/MA23899A1/fr unknown
- 1996-06-06 TR TR96/00475A patent/TR970073A2/xx unknown
- 1996-06-07 CN CN96110490A patent/CN1118459C/zh not_active Expired - Fee Related
- 1996-06-07 JP JP8145236A patent/JP2721147B2/ja not_active Expired - Fee Related
- 1996-06-07 RU RU96111418/04A patent/RU2175322C2/ru not_active IP Right Cessation
- 1996-06-07 BR BR9602705A patent/BR9602705A/pt not_active IP Right Cessation
- 1996-06-07 SG SG1996010018A patent/SG45486A1/en unknown
- 1996-06-07 CA CA002178548A patent/CA2178548A1/en not_active Abandoned
- 1996-06-07 UY UY24257A patent/UY24257A1/es not_active IP Right Cessation
- 1996-06-07 CO CO96029677A patent/CO4700472A1/es unknown
- 1996-06-07 NO NO962412A patent/NO309424B1/no unknown
- 1996-06-07 MY MYPI96002314A patent/MY113499A/en unknown
- 1996-06-08 KR KR1019960020447A patent/KR100446877B1/ko not_active IP Right Cessation
- 1996-06-10 CZ CZ19961696A patent/CZ290004B6/cs not_active IP Right Cessation
- 1996-07-11 TW TW085108416A patent/TW340846B/zh active
- 1996-08-26 SA SA96170263A patent/SA96170263B1/ar unknown
-
1998
- 1998-12-21 HK HK98114167A patent/HK1013065A1/xx not_active IP Right Cessation
-
2001
- 2001-07-31 GR GR20010401157T patent/GR3036307T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR003428A1 (es) | Derivados de pirimidindiona o triazindiona como antagonista de los receptores adrenergenicos alfa1, procedimiento para su preparacion, composicion farmaceutica que los contiene y uso de dichos compuestos para la preparacion de medicamentos. | |
AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
AR040286A1 (es) | Proceso para la preparacion de pirimidinas sustituidas | |
ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
AR047682A1 (es) | Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina | |
ES2143238T3 (es) | Derivados de 1-(piperidinil disustituido en posiciones 1,2)-piperazinas sustituidas en posicion 4. | |
AR002012A1 (es) | Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto. | |
AR035557A1 (es) | Un metodo para el tratamiento de desordenes proliferativos de las celulas asociadas con una actividad alterada de la cinasa dependiente de las celulas, un derivado de 3-ureido-pirazol, un procedimiento para su preparacion y una composicion farmaceutica que comprende dicho derivado | |
AR016666A1 (es) | Derivados de pirimidinona, un procedimiento para su preparacion y una composicion farmaceutica que los contiene | |
AR002244A1 (es) | Nuevos derivados de [3-(4-fenilpiperacin-1-il)propilamino]-piridina y benceno como antagonistas de ó 1-andrenoceptores, una composicion farmaceuticaque los contiene, un procedimiento para su preparacion y empleo de los mismos. | |
AR033793A1 (es) | Compuestos derivados del benceno, su utilizacion, procedimientos para su preparacion y composiciones farmaceuticas que los contienen | |
AR012488A1 (es) | Un compuesto derivado de quino- y quinazolinas antagonistas del factor liberador de corticotropina, un procedimiento para su preparacion, unacomposicion que los comprende, un procedimiento para la preparacion de dicha composicion, intermediarios y el uso de dichos compuestos para la fabricacion | |
ES2059873T3 (es) | 2-alquinilfenoles sustituidos con actividad antiinflamatoria, un procedimiento para su preparacion y sus composiciones farmaceuticas. | |
AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende | |
AR037681A1 (es) | Antagonistas receptores de adenosina a2a de 5-amino-[1,2,4]-triazol biciclico, composiciones farmaceuticas que los comprenden, el uso de las mismas, solo o en combinacion de los compuestos y otros agentes para la preparacion de medicamentos utiles en el tratamiento de la enfermedad de parkinson y un | |
DE60010596D1 (de) | Pyridinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
AR054707A1 (es) | Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
ES2046671T3 (es) | Un procedimiento para la preparacion de tetrahidroimidazo(1,4)benzodiazepin-2-tionas. | |
MX9306310A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
AR028743A1 (es) | DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA | |
ATE344230T1 (de) | Triphenylbutenderivate zur behandlung von neurologischen störungen | |
AR004691A1 (es) | Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion | |
CO5611104A2 (es) | Derivados azabiciclicos, azatriciciclos y azaespirociclicos de aminociclohexano como antagonistas de los receptores de nmda, 5ht3 y nicotinicos neuronales | |
ES2187783T3 (es) | Derivados de indolina utiles como antagonistas del receptor 5-ht-2c. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |